Clearside Biomedical, headquartered in Alpharetta, Georgia, specializes in therapies delivered to the eye via the suprachoroidal space and has developed the approved product XIPERE. The company’s lead program, CLS-AX, is in Phase 2b clinical testing for wet AMD.
CLSD filed a patent for "methods for treating ocular disorder with integrin antagonist composition" on Mon, April 24, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
